Abstract
The immunoreactivity for Ki-67 and PCNA was investigated in 487 patients with primary breast carcinomas using MIB-1 (Immunotech, France) and PC-10 (DAKO, Denmark) as primary antibodies. Formalin-fixed and paraffin-embedded tissue sections were used. The immunoreactivity for Ki-67 and PCNA was found to be independent of the length of fixation if the sections were pretreated in a microwave oven in citrate buffer and distilled water, respectively. The immunostaining was evaluated semiquantitatively.
High Ki-67 score (more than 1% positive tumour cells) and PCNA over-expression (more than 25% positive tumour cells) were correlated with clinicopathological parameters such as large tumour size, high histological grade (poor differentiation), and absence of steroid hormone receptors, which are parameters of an aggressive phenotype of the tumour.
In univariate analysis of survival data, both Ki-67 and PCNA were parameters of a poor overall survival in both lymph node-positive and -negative patients.
In multivariate analysis using a Cox model stratified by nodal status, Ki-67 and PCNA failed to be of prognostic significance whereas classical histopathological parameters such as tumour size and histological grade turned out to be of independent prognostic significance in both lymph node-positive and -negative patients, while progesterone receptors were of independent prognostic significance only in lymph node-positive patients.
Article PDF
Avoid common mistakes on your manuscript.
References
Ewertz M, Carstensen B: Trends in breast cancer incidence and mortality in Denmark, 1943–1982. Int J Cancer 41: 46–51, 1988
Rosai J: Ackerman's surgical pathology. The C.V. Mosby Company, St. Louis, 1989
Meyer J, McDivitt R, Stone K, Prey M, Bauer W: Practical breast carcinoma cell kinetics: a review and update. Breast Cancer Res Treat 4: 79–88, 1984
Meyer J, Province M: Proliferation index of breast carcinoma by thymidine labelling: prognostic power independent of stage, estrogen and progesterone receptor. Breast Cancer Res Treat 12: 191–204, 1988
Tubiana M, Koscielny S: Cell kinetics, growth rate and the natural history of breast cancer. The Heuson memorial lecture. Eur J Cancer Clin Oncol 24: 9–14, 1988
Tubiana M, Pejovic M, Koscielny S, Chvaudra N, Malaise E: Growth rate, kinetics of tumour cell proliferation and long-term outcome in human breast cancer. Int J Cancer 44: 17–22, 1989
Tubiana M, Courdi A: Cell proliferation kinetics in human solid tumours: relation to probability of metastasis, dissemination, and long-term survival. Radiother Oncol 15: 1–18, 1989
McGuire W, Tandon A, Allred DC, Chamness G, Clark G: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82:1006–1015,1990
Graem N, Helweg-Larsen K: Mitotic activity and delay in fixation of tissues. Acta Pathol Microbiol Scand (A) 87: 375–379, 1979
Donhuijsen K, Schmidt U, Horche H, van Beuningen D, Budach V: Changes in mitotic rate and cell cycle fractions caused by delayed fixation. Hum Pathol 21: 709–714, 1990
Clayton F: Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal carcinomas: mitotic count is the best single predictor. Cancer 68: 1309–1317, 1991
Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715, 1984
Gerdes J, Lelle R, Pickartz H, Heidenreich W, Schwarting R, Kurtsiefer L, Stauch G, Stein H: Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol 39: 977–980, 1986
Mathews M, Bernstein R, Franza B, Garrels J: Identity of the proliferating cell nuclear antigen and cyclin. Nature 303: 374–376, 1984
Celis J, Bravo R, Larsen P, Fey SJ: Cyclin: a nuclear protein whose level correlates with the proliferative state of normal as well as transformed cells. Leuk Res 8: 143–147, 1984
Garcia R, Coltera M, Gown A: Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Am J Pathol 134: 733–739, 1989
Siitonen S, Kallioniemi O-P, Isola J: Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer. Am J Pathol 142: 1081–1089, 1993
Battersby S, Andersson T: Correlation of proliferative activity in breast tissue using PCNA/cyclin. Hum Pathol 21: 781, 1990
Haerslev T, Jacobsen GK: Proliferating cell nuclear antigen (PCNA) in breast carcinomas. An immunohistochemical study with correlation to histopathological features and prognostic factors. Virchow Archiv A 424: 39–46, 1994
Dervan P, Magee H, Buckley C, Carney D: Proliferating cell nuclear antigen counts in formalin-fixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue. Am J Clin Pathol 97: S21-S28, 1992
Andersen K, Mouridsen H, Castberg T, Fischerman K, Andersen J, Hou-Jensen K, Brincker H, Johansen H, Henriksen E, Rorth M, Rossing N: Organization of the Danish adjuvant trials in breast cancer. Danish Med Bull 28: 102–106, 1981
World Health Organization: Histological typing of breast tumours. WHO, Geneva, 1968
Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359–377, 1957
Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958
Cox D, Oakes D: Analysis of survival data. London, 1984
Haerslev T, Jacobsen GK: Microwave processing for immunohistochemical demonstration of proliferating cell nuclear antigen (PCNA) in formalin-fixed and paraffin-embedded tissue. APMIS 102: 395–400, 1994
Sabatti E, Gerdes J, Ghelinzoni F, Poggi S, Zucchini L, Melili G, Grigioni F, Del Vecchio M, Leoncini L, Falini B, Pileri S: Comparison between the monoclonal antibodies Ki-67 and PC-10 in 125 malignant lymphomas. J Pathol 169: 397–403, 1993
Yu CC-W, Wilkinson N, Brito MJ, Buckley C, Fox H, Levison D: Patterns of immunohistochemical staining for proliferating nuclear antigen and p53 in benign and neoplastic human endometrium. Histopathology 23: 367–371, 1993
Cattoretti G, Becker M, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357–363, 1992
Kurki P, Vanderlaan M, Dolbeare F, Gray J, Tan E: Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 166: 209–219, 1986
Siitonen S, Isola J, Rantala I, Helin H: Intratumor variation in cell proliferation in breast carcinoma as determined by anti-PCNA monoclonal antibody and automated image analysis. Am J Clin Pathol 99: 226–231, 1993
Suzuki K, Katoh R, Kawaoki A: Immunohistochemical demonstration of proliferating cell nuclear antigen (PCNA) in formalin-fixed, paraffin-embedded sections from rat and human tissues. Acta Histochem Cytochem 25: 13–21, 1992
Leong A-Y, Milios J, Tang S: Is immunolocalisation of proliferating cell nuclear antigen (PCNA) in paraffin sections a valid index of cell proliferation? Appl Immunohistochem 12: 127–135, 1993
He W, Meyer JS, Scrivner DL, Koehm S, Hughes J: Assessment of proliferating cell nuclear antigen (PCNA) in breast cancer using anti-PCNA PC10 and 19A2: correlation with 5-bromo-2′-deoxyuridine or tritiated thymidine labeling and flow cytometric analysis. Biotech & Histochem 69: 203–212, 1994
Barnard N, Hall P, Lemoine N, Kadar N: Proliferative index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to clinical and pathological variables. J Pathol 152: 287–295, 1987
Locker A, Birrell K, Bell J, Nicholson R, Elston C, Blamey R, Ellis I: Ki67 immunoreactivity in breast carcinoma: relationship to prognostic variables and short term survival. Eur J Surg Oncol 18: 224–229, 1992
Vielh P, Chevillard S, Mosseri V, Donatini B, Magdelenat H: Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors. Am J Clin Pathol 94: 681–686, 1990
Tahan S, Neuberg D, Dieffenbach A, Yacoub L: Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 71: 3552–3559, 1993
Mango W, Hirchfield L, Bhuiya T, Harrison G, Mir R: Correlation of proliferating cell nuclear antigen (PCNA) and Ki-67 reactivity in primary breast carcinoma with hormone and disease-free survival. Conn Med 56: 667–669, 1992
Linden MD, Ma CK, Kubus J, Brown RD, Zarbo RJ: Ki-67 and proliferating cell nuclear antigen, tumour proliferative indices in DNA diploid colorectal adenocarcinomas. Correlation with histopathologic characteristics and cell cycle analysis with two-color DNA flow cytometry. Am J Clin Pathol 100: 206–212, 1993
Bravo R, MacDonald H: Existence of two populations of cyclins/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites. J Cell Biol 105: 1549–1554, 1987
Aaltomaa S, Lipponen P, Eskelinen M, Kosma V-M, Marin S, Alhava E, Syrjänen K: Prognostic factors after 5 years follow-up in female breast cancer. Oncology 49: 49, 1993
Weikel W, Beck T, Mitze M, Knapstein P: Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 18: 149–154, 1991
Gasparini S, Meli S, Pozza S, Cazzavilillan S, Beliacqua P: PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinomas. Growth Res 2: 145–150, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haerslev, T., Jacobsen, G.K. & Zedeler, K. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Tr 37, 101–113 (1996). https://doi.org/10.1007/BF01806492
Issue Date:
DOI: https://doi.org/10.1007/BF01806492